Amy S. Clark, MD, MSCE
Medical Oncology
Headshot of Amy S. Clark, MD, MSCE

Amy S. Clark, MD, MSCE

Medical Oncology
Accepting new patients
Sees patients age 18 and up
Rena Rowan Breast Center
Headshot of Amy S. Clark, MD, MSCE
Penn Medicine Provider

About me

  • Deputy Director, Breast Cancer Clinical Trials
  • Jill and Alan Miller Associate Professor in Breast Cancer Excellence

My education and training

  • Penn State Milton S. Hershey Medical CenterMedical School
  • Boston Medical CenterResidency
  • University of Pennsylvania Health SystemFellowship

Spoken languages

English
English

Reviews

Average Rating

495 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
October 2026
Dr Clark was very knowledgeable and gave me guidance in dealing with my diagnosis.
Anonymous
October 2026
Dr. Clark is very thorough and knowledgeable and caring.
Anonymous
October 2026
Dr Clark recognizes me not only as being a patient but as an individual.She has acknowledged me on the elevator and corridors in passing when I'm at the facility for other treatments. That speaks volumes to me about the level of dedication and commitment to patient care as she tends to numerous patients daily.
Anonymous
October 2026
She is thorough.

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Clark is a Penn Medicine provider.

Qualifications and experience

All conditions and treatments

Research

Publications

Segui E, Garcia-Cortés D, Gomez Tejeda Zañudo J, Shi R, Dang CT, Santa-Maria C, Westbrook KE, Abramson VG, Murthy RK, Nanda R, Rugo HS, Clark AS, Mainor C, Dees E, Hoyos V, Miller KD, Stringer-Reasor EM, Hunter NB, Oh S, Tarantino P, Baginska J, Patel A, Mohammed-Abreu A, Rahman T, DeMeo MK, Lin NU, Rimawi MF, Wolff AC, Mittendorf EA, Tolaney SM, Regan MM, Loi S, Abravanel DL, Goel S, Krop IE, Waks AG. Genomic landscape of HER2-positive (HER2+) metastatic breast cancer (MBC): analyses from the AVIATOR trial (TBCRC045) , San Antonio Breast Cancer Symposium: 2026,P3-13-21


I-SPY2 Trial Investigators and Advocates; O'Sullivan CC, Kalinsky KM, Yau C, Kulkarni T, Yee D, Wallace AM, Chien AJ, Boughey JC, Elias AD, Nanda R, Isaacs C, Omene C, Stringer-Reasor E, Clark AS, Thomas A, Han HS, Chan N, Williams N, Trivedi MS, Arora M, Vaklavas C, Tseng J, Bommakanti S, Anampa Mesias JD, Zimmer A, Falkson C, Torres ER, Nangia C, Albain KS, Rozenblit M, Zare S, Fazelli S, Chen YY, Huppert LA, Church AL, Beckwith H, Carroll E, Solanki M, Borges VF, Tevis SEA, Chen N, Zeck JC, Kowzun MJ, Sullivan J, Marshall N, Klein ME, Giridhar KV, Acharya-Leon R, Fan B, Walsh EM, Litvak A, Jahan N, McDonald E, Douglas EH, Zena J, Guth A, Johnson K, McGuinness JE, Matsuda K, Shakeri S, Krishnamurthy J, Kang I, Madans A, Feldman S, Johnson M, Katerji H, Ma Y, Matthews JB, Delson AL, LeStage B, Perlmutter J, Petricoin EF, Shatsky RA, Price E, Basu A, Asare AL, Helsten T, McNatt MH, Mukhtar RA, Symmans WF, Borowsky AD, Heshman DL, DeMichele AM, Rugo HS, Hylton NM, van 't Veer LJ, Esserman LJ Rilvegostomig Plus Trastuzumab-Deruxtecan for Early-Stage Breast Cancer , JAMA Oncol: 2026,e264258


Isaacs C, Nanda R, Yau C, Chien AJ, Hershman DL, Stringer-Reasor EM, Wallace AM, Thomas A, Vaklavas C, Clark AS, Kennedy LC, Sanford A, Boughey JC, Albain KS, Pusztai L, Kalinsky KM, Beckwith H, Williams NO, Han HS, Falkson C, Arora M, Elias AD, Pohlmann PR, Rozenblit M, Marshall N, Chen YY, Trivedi MS, McGuinness JE, Howard FM, Chen N, Khoury K, Lancaster RB, Yeung KT, Douglas E, Wei M, Mainor C, LeStage B, Delson AL, Asare AL, Brown-Swigart L, Hirst GL, Matthews JB, Perlmutter J, Symmans WF, Yee D, Hylton NM, van 't Veer LJ, Rugo HS, DeMichele AM, Berry DA, Esserman LJ. Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial , JAMA Oncol, 12(9): 2026,1008-1017


Magbanua MJM, Wolf DM, Yau C, Manon NA, Sayaman RW, Brown Swigart L, Hirst G, Li W, Isaacs C, Shatsky R, Clark AS, Zimmer A, Mukhtar R, Delson AL, Perlmutter J, Pohlmann PR, Hylton NM, Nanda R, Yee D, Symmans WF, Esserman LJ, Rugo HS, DeMichele A, van 't Veer LJ. Circulating tumor DNA concentration at diagnosis is a modifiable prognostic factor for distant metastatic recurrence in patients with high-risk breast cancer receiving neoadjuvant therapy , medRxiv [Preprint]: 2026


Ana C. Garrido-Castro1, Tianyu Li2, Se Eun Kim2, Jennifer Desrosiers1, Rita Nanda3, Yara Abdou4, Amy S. Clark5, Ruth Sacks6, Thomas O’Connor1, Natalie Sinclair1, Steve Lo7, Grace Audahl1, Eileen Wrabel1, Tess O’Meara1, Tanya E. Keenan1,8*, Nancy U. Lin1, Harold J. Burstein1, Elizabeth A. Mittendorf1, Nabihah Tayob2, Sara M. Tolaney1 SACI-IO HR+: Final results from a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in hormone receptor-positive/HER2-negative metastatic breast cancer , ESMO Open, 11(Supplement 4): 2026,107447


Shen J, Linn KA, Clark AS, Mamtani R, Hubbard RA. Missingness in Eligibility Criteria for Target Trial Emulation in EHR with Survival Outcomes , Stat Med, 45(8-9): 2026


Phun J, Clark A, Zhang J, Nayak, A. Discordant HER2 Results Highlight the Need for Compulsory Biomarker Slide Review in Breast Cancer Referrals , Laboratory Investigation, 106(3): 2026,104474


Bild AH, Sangar MC, McQuerry JA, Ideker T, Kopetz S, Carey L, Nath A, Marcus D, Regier A, Rashid N, Barzilay R, Winer E, Salgia R, Malhotra J, Gentles A, Buetow K, Mahmood F, Markman DW, Eddy JA; ADAPT Consortium. The ADAPT learning cancer treatment system: ARPA-H's initiative to revolutionize cancer therapy , Cancer Cell, 44(3): 2026,449-454


Stringer-Reasor E, Li Y, Zhang J, Rocque G, Jones K, O'Sullivan C, Giridhar K, Dees EC, Nanda R, Hunter N, Clark A, Wolff A, Krop I, Lin N, Rimawi MF, Yang ES. CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy , J Natl Compr Canc Netw., 24(3.5): 2026,CLO26-104


J. Tchou, A. Nayak, H. N. Xu, J. Kollmar, E. H. Smith, M. Z. Mazur, L. Keele, A. Clark, N. Taunk, J. Fraietta, the BreastVax Study Team Abstract PS4-07-15: A single preoperative pembrolizumab dose plus a single subablative radiotherapy fraction (7 Gy) elicits anti-tumor immune response and increases stromal tumor infiltrating lymphocytes in triple negative breast cancer: a phase 1b/2 study , Clin Cancer Res, 32(4 suppl): 2026,PS4-07-15